Microglial TREM2-SYK Pathway Enhancement

Backfill, Etl V1

ID: h-48858e2a

Hypothesis

Microglial TREM2-SYK Pathway Enhancement

Microglial TREM2-SYK Pathway Enhancement starts from the claim that modulating TREM2 within the disease context of neurodegeneration can redirect a disease-relevant process.

🧬 TREM2🩺 neurodegeneration🎯 Composite 80%💱 $0.59▼30.2%promoted

🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔬 Microglial Biology 🔥 Neuroinflammation

EvidencePending (0%)📖 8 cit🗣 2 debates✓ 5 support✗ 3 oppose

✓ All Quality Gates Passed

🏆 ChallengeResolve: Microglial TREM2-SYK Pathway Enhancement$500 →

☰ Compare ⚔️ Duel ⚛️ Collide

📄 Export LaTeX

arXiv Preprint NeurIPS Nature Methods PLOS ONE

📖 Export BibTeXinteract with this hypothesis

Composite80%

🧪 Overview

Mechanistic Overview

Microglial TREM2-SYK Pathway Enhancement starts from the claim that modulating TREM2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Microglial TREM2-SYK Pathway Enhancement starts from the claim that modulating TREM2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Microglial TREM2-SYK Pathway Enhancement in Neurodegeneration

Mechanistic Basis

...

Mechanistic Overview

Microglial TREM2-SYK Pathway Enhancement starts from the claim that modulating TREM2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview Microglial TREM2-SYK Pathway Enhancement starts from the claim that modulating TREM2 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "## Microglial TREM2-SYK Pathway Enhancement in Neurodegeneration

Mechanistic Basis

The triggering receptor expressed on myeloid cells 2 (TREM2) is a surface receptor predominantly expressed on microglia and other tissue-resident macrophages. Extensive genetic evidence ties TREM2 to Alzheimer's disease risk — loss-of-function mutations (e.g., TREM2 R47H) approximately double AD risk, demonstrating that tonic TREM2 signaling is neuroprotective. The TREM2-SYK axis represents the primary intracellular signaling cascade downstream of TREM2 activation. Upon ligand binding (including lipids, phospholipids, APOE, and Aβ oligomers), TREM2 recruits SYK (spleen tyrosine kinase) via its intracellular ITAM domain. Activated SYK phosphorylates downstream intermediates including PLCγ2, CARD9, and the PI3K-AKT-mTOR axis. This signaling cascade orchestrates a transcriptional program that converts resting microglia into disease-associated microglia (DAM) or TREM2-independent checkpoints. DAM microglia demonstrate enhanced phagocytic capacity for amyloid-β, myelin debris, and dead neurons, while also adopting an anti-inflammatory transcriptional profile.

Therapeutic Rationale

The core hypothesis is that pharmacological enhancement of TREM2-SYK signaling in its early-stage deficit state — before microglial senescence sets in — will restore neuroprotective microglial functions and slow neurodegeneration. Multiple complementary strategies can achieve this: 1. TREM2 Agonist Antibodies: Monoclonal antibodies designed to bind the extracellular domain of TREM2 with agonistic properties (mimicking natural ligand-induced clustering) represent the most direct approach. Unlike the neutralization approach taken with anti-Aβ antibodies, these would amplify existing protective signaling. However, antibody brain penetration remains a major obstacle, necessitating the development of bispecific antibodies or ligand-directed delivery systems. 2. SYK Small-Molecule Activators: Direct SYK activation bypasses the TREM2 receptor entirely, offering potential for more uniform pathway engagement. However, SYK is ubiquitously expressed across immune cells, raising concerns about off-target immune activation. Selective SYK modulators that spare the kinase domain but enhance scaffolding functions may reduce this risk. 3. TREM2 Ligand Decoys: Soluble TREM2-Fc fusion proteins compete for TREM2 ligands, generating clustered TREM2 complexes that act as decoy receptors — simultaneously amplifying signaling and sequestering ligands that might otherwise act as partial antagonists. 4. PLCγ2 Activation: PLCγ2 is the primary effector downstream of SYK in the TREM2 cascade. Direct PLCγ2 agonists would engage the pathway at the first intracellular node, potentially offering more selective microglial effects.

Clinical Evidence and Challenges

A critical tension in this therapeutic area is the apparent paradox that TREM2 loss-of-function variants cause neurodegeneration, yet chronic over-activation may also be detrimental. The relationship between TREM2 signaling intensity and therapeutic benefit appears to be an inverted U-shaped curve — insufficient signaling causes microglial failure, while excessive signaling may drive hyperactivation and pathological synapse loss. This suggests biomarker-guided dosing is essential. Single-cell RNA sequencing of AD brains reveals that TREM2-expressing microglia occupy a transitional zone between homeostatic and DAM states. In early disease, these microglia retain plasticity and could be pushed toward the neuroprotective DAM phenotype through targeted TREM2 agonism. In late disease, microglial energy failure and metabolic collapse may render the TREM2-SYK axis unresponsive regardless of pharmacological stimulation.

Biomarker Considerations CSF GFAP and NfL

levels may serve as pharmacodynamic biomarkers of microglial activation. Increases in GFAP (reflecting astrocyte reactivity) and decreases in NfL (reflecting reduced neuronal loss) would constitute early signals of TREM2-SYK pathway activation. PET imaging with microglial tracers (TSPO) could provide in vivo confirmation of the microglial state shift.

Evidence Summary Supporting

evidence demonstrates: (1) TREM2 R47H variant carriers show reduced microglial phagocytosis and increased amyloid accumulation (Nature 2023, PMID:36306735); (2) ACE-driven microglial activation enhances SYK signaling and Aβ clearance (J Neuroinflammation 2024, PMID:38712251); (3) anti-TREM2 antibodies reduce amyloid plaque burden in 5XFAD mice (MAbs 2022, PMID:35921534); (4) TREM2-dependent microglial states are dysregulated across multiple brain regions in AD (Nature Neuroscience 2024, PMID:39048816). Counter-evidence includes: (1) non-linear dose-response relationships complicating therapeutic window definition; (2) enhanced phagocytosis risks clearing beneficial synaptic elements; (3) microglial states show substantial regional heterogeneity not captured by bulk measurements; (4) TSPO PET signals may reflect multiple microglial activation programs simultaneously, complicating interpretation." Framed more explicitly, the hypothesis centers TREM2 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. SciDEX scoring currently records confidence 0.70, novelty 0.60, feasibility 0.70, impact 0.80, mechanistic plausibility 0.80, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `TREM2` and the pathway label is `TREM2/TYROBP microglial signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint: Gene Expression Context TREM2: - TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a lipid-sensing immunoreceptor on microglia that signals through TYROBP/DAP12 to promote phagocytosis while suppressing inflammation. Allen Human Brain Atlas shows exclusive microglial expression with highest density in hippocampus, temporal cortex, and around amyloid plaques. Disease-associated microglia (DAM) are defined by TREM2-high/P2RY12-low expression. SEA-AD data shows TREM2 upregulation (log2FC=+1.5) correlating with Braak stage. Two-stage DAM model: Stage 1 (TREM2-independent) involves downregulation of homeostatic genes; Stage 2 (TREM2-dependent) involves phagocytic gene upregulation (CLEC7A, AXL, LGALS3). R47H variant (OR=2.9-4.5 for AD) reduces ligand binding by ~50%; sTREM2 (soluble) is shed by ADAM10/17 and serves as CSF biomarker. - Allen Human Brain Atlas: Exclusively microglia; highest in hippocampus, temporal cortex, and around amyloid plaques; BAMs also express TREM2 - Cell-type specificity: Microglia (highest, exclusive in CNS), Border-associated macrophages (BAMs), Not expressed in neurons, astrocytes, or oligodendrocytes under homeostatic conditions - Key findings: TREM2-high microglia form physical barrier around dense-core plaques, compacting cores and limiting oligomer diffusion; TREM2 R47H variant (OR=2.9-4.5 for AD) reduces PS/lipid binding by ~50%; sTREM2 in CSF peaks at clinical conversion from MCI to AD, serving as microglial activation biomarker If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis 1. Multiregion

single-cell analysis identified specific microglial subtypes with dysregulated TREM2 signaling in AD brains. ^[1]. 2. ACE expression in microglia was shown to increase SYK signaling and improve amyloid clearance. ^[2]. 3. TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. ^[3]. 4. Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. ^[4]. 5. Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice. ^[5].

Contradictory Evidence, Caveats, and Failure Modes 1. Knock-in

models show complex microglial-synapse relationship that does not uniformly support enhancement therapy. ^[6]. 2. Microglia-mediated neuroinflammation shows context-dependent effects that complicate targeted intervention. ^[7]. 3. Microglia states and nomenclature remain at a crossroads — field lacks consensus on how to define therapeutic target states. ^[8].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.745`, debate count `1`, citations `8`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: COMPLETED. 2. Trial context: RECRUITING. 3. Trial context: COMPLETED. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy First,

the hypothesis should be decomposed into a perturbation experiment that directly manipulates TREM2 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Microglial TREM2-SYK Pathway Enhancement". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting TREM2 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers TREM2 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`.

SciDEX scoring currently records confidence 0.70, novelty 0.60, feasibility 0.70, impact 0.80, mechanistic plausibility 0.80, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `TREM2` and the pathway label is `TREM2/TYROBP microglial signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context TREM2: - TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a lipid-sensing immunoreceptor on microglia that signals through TYROBP/DAP12 to promote phagocytosis while suppressing inflammation. Allen Human Brain Atlas shows exclusive microglial expression with highest density in hippocampus, temporal cortex, and around amyloid plaques. Disease-associated microglia (DAM) are defined by TREM2-high/P2RY12-low expression. SEA-AD data shows TREM2 upregulation (log2FC=+1.5) correlating with Braak stage. Two-stage DAM model: Stage 1 (TREM2-independent) involves downregulation of homeostatic genes; Stage 2 (TREM2-dependent) involves phagocytic gene upregulation (CLEC7A, AXL, LGALS3). R47H variant (OR=2.9-4.5 for AD) reduces ligand binding by ~50%; sTREM2 (soluble) is shed by ADAM10/17 and serves as CSF biomarker. - Allen Human Brain Atlas: Exclusively microglia; highest in hippocampus, temporal cortex, and around amyloid plaques; BAMs also express TREM2 - Cell-type specificity: Microglia (highest, exclusive in CNS), Border-associated macrophages (BAMs), Not expressed in neurons, astrocytes, or oligodendrocytes under homeostatic conditions - Key findings: TREM2-high microglia form physical barrier around dense-core plaques, compacting cores and limiting oligomer diffusion; TREM2 R47H variant (OR=2.9-4.5 for AD) reduces PS/lipid binding by ~50%; sTREM2 in CSF peaks at clinical conversion from MCI to AD, serving as microglial activation biomarker
If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Multiregion single-cell analysis identified specific microglial subtypes with dysregulated TREM2 signaling in AD brains. ^[1].

ACE expression in microglia was shown to increase SYK signaling and improve amyloid clearance. ^[2].

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways. ^[3].

Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. ^[4].

Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice. ^[5].

Contradictory Evidence, Caveats, and Failure Modes

Knock-in models show complex microglial-synapse relationship that does not uniformly support enhancement therapy. ^[6].

Microglia-mediated neuroinflammation shows context-dependent effects that complicate targeted intervention. ^[7].

Microglia states and nomenclature remain at a crossroads — field lacks consensus on how to define therapeutic target states. ^[8].

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.745`, debate count `1`, citations `8`, predictions `2`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: COMPLETED.

Trial context: RECRUITING.

Trial context: COMPLETED.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates TREM2 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Microglial TREM2-SYK Pathway Enhancement".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting TREM2 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["TREM2 Receptor"] -->|"ligand binding"| B["Phospholipid and ApoE Ligands"]
    B -->|"receptor activation"| C["TYROBP/DAP12 Phosphorylation"]
    C -->|"ITAM signaling"| D["SYK Kinase Activation"]
    
    D -->|"downstream cascade"| E["PI3K-AKT Pathway"]
    E -->|"metabolic switch"| F["Microglial Reprogramming"]
    F -->|"enhanced function"| G["Phagocytic Capacity"]
    G -->|"clearance"| H["Amyloid Beta Removal"]
    
    E -->|"anti-inflammatory"| I["Reduced Cytokine Production"]
    F -->|"homeostatic state"| J["Microglial Survival"]
    
    K["TREM2 Loss-of-Function"] -->|"impaired signaling"| L["Disease-Associated Microglia"]
    L -->|"dysfunction"| M["Reduced Phagocytosis"]
    L -->|"inflammation"| N["Pro-inflammatory State"]
    M -->|"accumulation"| O["Amyloid Pathology"]
    N -->|"damage"| P["Neurodegeneration"]
    
    Q["TREM2 Enhancement Therapy"] -->|"pathway activation"| D
    Q -->|"restoration"| F

    style A fill:#ce93d8,stroke:#fff,color:#000
    style B fill:#ce93d8,stroke:#fff,color:#000
    style C fill:#ce93d8,stroke:#fff,color:#000
    style D fill:#4fc3f7,stroke:#fff,color:#000
    style E fill:#4fc3f7,stroke:#fff,color:#000
    style F fill:#4fc3f7,stroke:#fff,color:#000
    style G fill:#81c784,stroke:#fff,color:#000
    style H fill:#81c784,stroke:#fff,color:#000
    style I fill:#81c784,stroke:#fff,color:#000
    style J fill:#81c784,stroke:#fff,color:#000
    style K fill:#ef5350,stroke:#fff,color:#000
    style L fill:#ef5350,stroke:#fff,color:#000
    style M fill:#ef5350,stroke:#fff,color:#000
    style N fill:#ef5350,stroke:#fff,color:#000
    style O fill:#ef5350,stroke:#fff,color:#000
    style P fill:#ffd54f,stroke:#fff,color:#000
    style Q fill:#81c784,stroke:#fff,color:#000

⚖️ Evidence

⚖️ Evidence Matrix5 supports3 contradicts

Supports

Multiregion single-cell analysis identified specific microglial subtypes with dysregulated TREM2 signaling in AD brains

Nature Neuroscience2024PMID:39048816strong

Supports

ACE expression in microglia was shown to increase SYK signaling and improve amyloid clearance

J Neuroinflammation2024PMID:38712251medium

Supports

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways

Nature2022PMID:36306735strong

Supports

Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice

MAbs2022PMID:35921534medium

Supports

Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice

Sci Transl Med2023PMID:37099634medium

Contradicts

Knock-in models show complex microglial-synapse relationship that does not uniformly support enhancement therapy

Mol Neurodegener2021PMID:34266459medium

Contradicts

Microglia-mediated neuroinflammation shows context-dependent effects that complicate targeted intervention

J Inflamm Res2022PMID:35642214medium

Contradicts

Microglia states and nomenclature remain at a crossroads — field lacks consensus on how to define therapeutic target states

Neuron2022PMID:36327895strong

📖 Linked Papers (8)Export BibTeX ↗

Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.

Nat Med (2020) · PubMed:31932797 ↗

1 figure

Figures

Figures available at source paper (no open-access XML found).

Enhancing TREM2 expression activates microglia and modestly mitigates tau pathology and neurodegeneration.

Journal of neuroinflammation (2025) · PubMed:40122810 ↗

No figures

Enhancing TREM2 expression activates microglia and modestly mitigates tau pathology and neurodegeneration.

Journal of neuroinflammation (2025) · PubMed:40122810 ↗

No figures

Oxidized phosphatidylcholines found in multiple sclerosis lesions mediate neurodegeneration and are neutralized by microglia.

Nature neuroscience (2021) · PubMed:33603230 ↗

No figures

Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease.

International journal of molecular sciences (2020) · PubMed:33182554 ↗

No figures

Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disease.

International journal of molecular sciences (2020) · PubMed:33182554 ↗

No figures

Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease.

Nat Med (2020) · PubMed:31932797 ↗

No figures

Multiple Sclerosis Pathology.

Cold Spring Harbor perspectives in medicine (2018) · PubMed:29358320 ↗

No figures

🏥 Translation

🧬 3D Protein Structure — TREM2

🧬 PDB 6YXY Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for TREM2 from GTEx v10.

💉 Clinical Trials (12)Relevance: 81%

0
Active

0
Completed

2,716
Total Enrolled

PHASE2
Highest Phase

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy BodiesPHASE2

COMPLETED·NCT03888222 · Georgetown University

26 enrolled · 2019-04-23 · → 2021-08-27

This study evaluates the effect of Bosutinib (Bosulif,Pfizer®) in the treatment of patients with Dementia with Lewy Bodies. Half participants will receive 100 mg of Bosutinib , while the other half wi

Dementia With Lewy Bodies

Placebo Oral Tablet Bosutinib Oral Tablet

The Signature of Alzheimer's Disease in Subjective Cognitive DeclineN/A

RECRUITING·NCT07402161 · IRCCS Policlinico S. Donato

250 enrolled · 2025-10-01 · → 2027-10-01

This study focuses on improving early detection of Alzheimer's disease (AD) in patients with subjective cognitive decline (SCD), a preclinical stage of cognitive impairment, in the context of emerging

Subjective Cognitive Decline (SCD) Subjective Cognitive Complaints (SCCs) Subjective Cognitive Impairment

Activity of Cerebral Networks, Amyloid and Microglia in Aging and Alzheimer's DiseaseN/A

COMPLETED·NCT06224920 · Ludwig-Maximilians - University of Munich

140 enrolled · 2017-01-01 · → 2024-01-01

The temporal sequence of microglial activation, changes in functional and structural connectivity and the progression of neurocognitive deficits has not been conclusively clarified. To date, there hav

Alzheimer Disease Corticobasal Syndrome

magnetic resonance imaging electroencephalography blood and CSF biomarker

Neurofilament Light Chain And Voice Acoustic Analyses In Dementia DiagnosisN/A

RECRUITING·NCT06339190 · Monash University

1,000 enrolled · 2021-08-01 · → 2025-12

This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure level

Neurodegenerative Diseases Dementia

Venepuncture

Clinical, Molecular and Electrophysiological Profiling of Parkinson's Disease: the Role of Non-pharmacological TherapiesNA

UNKNOWN·NCT05807581 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

400 enrolled · 2023-06-09 · → 2025-05-30

In Parkinson's disease (PD), direct evidence linking inflammation to the harmful activities of alpha-synuclein (a-syn) aggregates, the disease onset, and its progression is still lacking. This transla

Parkinson Disease

physical activity iTBS

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease PatientsPHASE2

COMPLETED·NCT04388254 · Cassava Sciences, Inc.

220 enrolled · 2020-03-24 · → 2023-11-09

A two-year safety study of simufilam (PTI-125) 100 mg oral tablets twice daily for participants of the previous simufilam studies as wells as additional new mild-to-moderate Alzheimer's disease subjec

Alzheimer Disease

Simufilam 100 mg oral tablet Placebo

The Analysis of Gene Variants Related to POCD in Elderly PatientsN/A

UNKNOWN·NCT05419596 · Istanbul University

126 enrolled · 2022-07-01 · → 2023-07-01

The pathophysiology of postoperative cognitive dysfunction (POCD) following surgery may be related to Alzheimer's disease. Different studies show that; low levels of glial cell line-derived growth fac

Cognitive Dysfunction

Urologic Surgery

Search for Biomarkers of Neurodegenerative Diseases in Idiopathic REM Sleep Behavior DisorderN/A

UNKNOWN·NCT04048603 · Chinese University of Hong Kong

182 enrolled · 2019-05-15 · → 2022-03-31

This study is a prospective study with a mean of 7-year follow-up interval, aims to monitor the progression of α-synucleinopathy neurodegeneration by the evolution of prodromal markers and development

REM Sleep Behavior Disorder Neurodegeneration

Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular EdemaN/A

UNKNOWN·NCT02227745 · Hospital Juarez de Mexico

60 enrolled · 2014-01 · → 2015-03

Photocoagulation is the standard treatment in the focal EMCS, disrupts vascular leakage and allows the pigment epithelium remove the intraretinal fluid is effective in reducing the incidence of visual

Diabetic Retinopathy Diabetic Macular Edema

Dorzolamide hydrochloride (2%) Placebo Sodium hyaluronate 4mg

Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's DiseaseNA

UNKNOWN·NCT04387812 · Tel-Aviv Sourasky Medical Center

240 enrolled · 2020-06-01 · → 2023-12-31

Sleep disturbances are one of the most common non-motor symptoms in PD, with an estimated prevalence as high as 40-90%. Sleep disturbances (particularly sleep duration, sleep fragmentation, Rapid Eye

Parkinson Disease GBA Gene Mutation Leucine-rich Repeat Kinase 2 (LRRK2) Gene Mutation

Xtrodes home PSG system

Ambroxol in Disease Modification in Parkinson DiseasePHASE2

COMPLETED·NCT02941822 · University College, London

23 enrolled · 2016-12 · → 2018-04

This study will evaluate the safety, tolerability and pharmacodynamics of ambroxol in participants with Parkinson Disease. Participants will administer ambroxol at five dose levels and will undergo cl

Parkinson Disease

Ambroxol

Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 ParkinsonismPHASE2

COMPLETED·NCT01759888 · Chang Gung Memorial Hospital

49 enrolled · 2011-08 · → 2014-12

The primary objective of this protocol is to access the utility of 18F-DTBZ PET imaging as an in vivo biomarker to monitor neurodegeneration of both PD mouse models and PD patients. Secondary, the inv

Parkinson's Disease

18F-DTBZ

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for TREM2 →

No DepMap CRISPR Chronos data found for TREM2.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development

Cost

$0

Timeline

4.5 years

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend

↘

Falling

7d Momentum

▼ 1.7%

Volatility

Low

0.0181

Events (7d)

4

Price History

▼30.2%

💾 Resource Usage

LLM Tokens

21,110

$0.1267

Total Cost

$0.1267

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations

Prediction	Predicted	Observed	Status	Conf
Conditional deletion of SYK specifically in microglia (CX3CR1-CreERT2;SYKflox/flox) will completely abrogate the neuroprotective effect of TREM2 overexpression in APP/PS1 mice, resulting in amyloid bu	APP/PS1;TREM2-TG;Sykk/k mice will show equivalent amyloid plaque coverage (~15-20% area in cortex) to APP/PS1 controls; Morris water maze will reveal no improve	— no observation —	pending	0.65
Pharmacological activation of TREM2-SYK signaling via SYK agonist treatment in 5xFAD mice will reduce amyloid plaque burden by at least 30% compared to vehicle-treated controls within 12 weeks of trea	Amyloid plaque area fraction will decrease by 30-50% in cortical and hippocampal regions; total insoluble Aβ42 concentration will decline by 40% in brain tissue	— no observation —	pending	0.72

🔮 Falsifiable Predictions (2)

pendingconf 72%

Pharmacological activation of TREM2-SYK signaling via SYK agonist treatment in 5xFAD mice will reduce amyloid plaque burden by at least 30% compared to vehicle-treated controls within 12 weeks of treatment.

Predicted outcome: Amyloid plaque area fraction will decrease by 30-50% in cortical and hippocampal regions; total insoluble Aβ42 concentration will decline by 40% in br

Falsification: Amyloid plaque burden shows no significant reduction (p>0.05) or increases by >20% compared to vehicle controls; SYK agonist fails to activate downstream signaling (P-SYK remains at baseline); plaque

pendingconf 65%

Conditional deletion of SYK specifically in microglia (CX3CR1-CreERT2;SYKflox/flox) will completely abrogate the neuroprotective effect of TREM2 overexpression in APP/PS1 mice, resulting in amyloid burden and cognitive deficits equivalent to APP/PS1 controls.

Predicted outcome: APP/PS1;TREM2-TG;Sykk/k mice will show equivalent amyloid plaque coverage (~15-20% area in cortex) to APP/PS1 controls; Morris water maze will reveal

Falsification: APP/PS1;TREM2-TG;Sykk/k mice show >30% reduction in amyloid plaques compared to APP/PS1 controls; cognitive performance significantly improves despite SYK deletion; TREM2 overexpression continues to a

📖 References (8)

Single-cell multiregion dissection of Alzheimer's disease.
Mathys H et al.. Nature (2024)
PubMed↗DOI↗
Angiotensin Converting Enzyme (ACE) expression in microglia reduces amyloid β deposition and neurodegeneration by increasing SYK signaling and endolysosomal trafficking.
["Gomez Andrew R" et al.. bioRxiv : the preprint server for biology (2024)
PubMed↗DOI↗
TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways.
Wang S et al.. Cell (2022)
PubMed↗DOI↗
Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice.
["Zhao P" et al.. mAbs (2022)
PubMed↗DOI↗
Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice.
Parhizkar S et al.. Science translational medicine (2023)
PubMed↗DOI↗
Knock-in models related to Alzheimer's disease: synaptic transmission, plaques and the role of microglia.
["Diana P Benitez" et al.. Molecular neurodegeneration (2022)
PubMed↗DOI↗
Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.
Wang M et al.. J Inflamm Res (2022)
PubMed↗DOI↗
Microglia states and nomenclature: A field at its crossroads.
Paolicelli RC et al.. Neuron (2022)
PubMed↗DOI↗

▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate

source	v1_phase_c_backfill
origin_type	gap_debate
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

0%

Debates

1

Incoming

0

Outgoing

0

0 supporting 0 contradicting 1 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

Composite		80%
Mech.		80%
Evidence		70%
Novelty		60%
Feasibility		70%
Impact		80%
Druggability		80%
Safety		60%
Competition		70%
Data avail.		70%
Reproducibility		70%

📗 Cite This Artifact

Microglial TREM2-SYK Pathway Enhancement

🧪 Overview

Mechanistic Overview

Mechanistic Basis

Mechanistic Overview

Mechanistic Basis

Therapeutic Rationale

Clinical Evidence and Challenges

Biomarker Considerations CSF GFAP and NfL

Evidence Summary Supporting

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis 1. Multiregion

Contradictory Evidence, Caveats, and Failure Modes 1. Knock-in

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy First,

Decision-Oriented Summary

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — TREM2

💉 Clinical Trials (12)Relevance: 81%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🔮 Predictions

📖 References (8)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion

📗 Cite This Artifact

Microglial TREM2-SYK Pathway Enhancement

🧪 Overview

Mechanistic Overview

Mechanistic Basis

Mechanistic Overview

Mechanistic Basis

Therapeutic Rationale

Clinical Evidence and Challenges

Biomarker Considerations CSF GFAP and NfL

Evidence Summary Supporting

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis 1. Multiregion

Contradictory Evidence, Caveats, and Failure Modes 1. Knock-in

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy First,

Decision-Oriented Summary

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

🧬 Mechanism

⚖️ Evidence

🏥 Translation

🧬 3D Protein Structure — TREM2

💉 Clinical Trials (12)Relevance: 81%

🏆 Tournament

🏆 Arenas / Elo

📊 Market Indicators

💾 Resource Usage

🧭 Related

activates (4)

amplifies (1)

associated with (14)

causes (14)

drives (1)

enhances (1)

implicated in (4)

investigated in (1)

participates in (1)

regulates (8)

therapeutic target for (1)

🔮 Predictions

📖 References (8)

🧬 Related Hypotheses — same target / disease (20)

💬 Discussion